TIHI NEPRIJATELJ IZ ŠAKE - VIKINŠKA BOLEST
Ključne reči:
Dipitrenova kontraktura, Vikinška bolest, klinička slika, dijagnoza, terapija
Sažetak
Dipitrenova kontraktura (DK) je progresivna idiopatska fibroza površinske palmarne fascije uzrokovana promenama u palmarnoj aponeurozi, koje rezultiraju fleksijskom kontrakturom prstiju ruke sa nemogućnošću ispružanja prstiju. Bolest poznata još iz doba Vikinga prisutna je u 8% svetske populacije, češća kod muškaraca a u njenoj etiologiji bitnu ulogu igra nasleđe koje pokazuje varijabilnu ekspresiju. Patogeneza DK još uvek je nerazjašnjena, a uključuje nastanak kolagenih čvorića koji progrediraju u fibrozne trake na mestima najvećeg pritiska između dermisa i fascije. Dijagnoza se postavlja samo kliničkim pregledom, a lečenje može biti konzervativno i hirurško. Konzervativno lečenje rezervisavo je za pacijente sa simptomima blažeg stepena i bez kontrakture prstiju, dok je hirurško lečenje zlatni standard u terapiji osoba kod kojih nastala kontraktura limitira funkcija šake i/ili fleksiju proksimalnog interfalangealnog zgloba za ≥15º i/ili metakarpofalangealnog zgloba za ≥30º. Cilj ovog rada je prikazati aktuelna saznanja vezana za DK.
Reference
1. Mitrović V. Dupuytrenova kontraktura – bolest Vikinga u suvremenom svijetu. Medicina fluminensis. 2023; 59(3): 229-40. doi: 10.21860/medflum2023_306340.
2. Elliot D. The early history of Dupuytren’s disease. Hand Clin. 1999;15(1):1-v.
3. Salari N, Heydari M, Hassanabadi M, Kazeminia M, Farshchian N, Niaparast M, et al. The worldwide prevalence of the Dupuytren disease: a comprehensive systematic review and meta-analysis. J Orthop Surg Res. 2020;15(1):495. doi: 10.1186/s13018-020-01999-7.
4. Ng M, Lawson DJ, Winney B, Furniss D. Is Dupuytren’s disease really a ‘disease of the Vikings’?. J Hand Surg Eur Vol. 2020;45:273-79. doi:10.1177/1753193419882851.
5. Ng M, Thakkar D, Southam L, Werker P, Ophoff R, Becker K et al. A genome-wide Association Study of Dupuytren Disease Reveals 17 Additional Variants Implicated in Fibrosis. Am J Hum Genet. 2017;101:417-27. doi:10.1016/j.ajhg.2017.08.006.
6. Todorović Z, Jovanović B, Stoiljković G. Dipitrenova kontraktura – naša iskustva. Apollinem medicum et aesculapium. 2012; 10(3):12-15.
7. Nikolić J, Janjić Z, Momčilovć D, Ninković S, Harhai V. Plantarna fibromatoza i Dupuytren-ova kontraktura kod adolescenta. Vojnosanit Pregl. 2011; 68(10):886-90. doi: 10.2298/VSP1110886N.
8. Fernando JJ, Fowler C, Graham T, Terry K, Grocott P, Sandford F. Pre-operative hand therapy management of Dupuytren's disease: A systematic review. Hand Ther. 2024;29(2):52-61. doi: 10.1177/17589983241227162.
9. Dutta A, Jayasinghe G, Deore S, Wahed K, Bhan K, Bakti N, et al. Dupuytren’s contracture—current concepts. J Clin Orthop Trauma. 2020;11(4):590-96. doi: 10.1016/j.jcot.2020.03.026.
10. Walthall J, Anand P, Rehman UH. Dupuytren Contracture. [Updated 2023 Feb 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526074/
11. Larocerie-Salgado J, Davidson J, Fenton P. Nonoperative Treatment of Dupuytren's Contracture: The Use of Ultrasound Imaging to Assess Efficacy. J Hand Microsurg. 2024;16(1):100003. doi:10.1055/s-0042-1748780
12. Lambi AG, Popoff SN, Benhaim P, Barbe MF. Pharmacotherapies in Dupuytren Disease: Current and Novel Strategies. J Hand Surg Am. 2023;48(8):810-21. doi:10.1016/j.jhsa.2023.02.003
13. Park JW, Kim ST, Lee KS, Gong HS. Vitamin D status in Dupuytren’s disease: Association with clinical status and vitamin D receptor expression. J Plast Reconstr Aesthet Surg. 2022; 75:1916-22. doi:10.1016/j.bjps.2022.01.012.
14. Yildiz S, Karacaoğlu E, Pehlivan O. Hyperbaric oxygen for the treatment of early-phase Dupuytren's contracture. Microsurgery. 2004;24(1):26-29. doi:10.1002/micr.10198.
15. Davis SM, Chang EY. Dupuytren's contracture treated with botulinum toxin A injection. Arch Clin Cases. 2021;7(4):63-67. doi: 10.22551/2020.29.0704.10175.
16. National Institute for Health and Care Excellence [Internet]. Nice: Radiation therapy for early Dupuytren’s disease. c2023 [cited 2021 Mar 8]. Available from: https://www.nice.org.uk/guidance/ipg573/resources/radiation-therapy-for-early-dupuytrens-disease-pdf-1899872106511813.
17. Reuttermann M, Hermann MR, Khatib Chatidi K, Werker PMN. Dupuytren’s Disease - Etiology and Treatment. Dtsch Arztebl Int. 2021;19:781-88. doi:10.3238/arztebl.m2021.0325.
18. Kuboi T, Tajika T, Endo F, Goto W, Nakajima I, Hasegawa S, et al. Collagenase Clostridium histolyticum Injection Therapy Improves Health-related Quality of Life in Patients with Dupuytren's Disease. Prog Rehabil Med. 2021;6:20210023. doi: 10.2490/prm.20210023.
19. Warwick D, Arner M, Pajardi G, Szabo Z, Masmejean EH, Fores J et al. Collagenase clostridium histolyticum in patients with Duppuytren’s contracture: results from POINT X, an open label study of clinical and patient reported outcomes. J Hand Surg Eur. 2015;40:124-32. doi:10.1177/1753193413519926.
20. Coleman S, Gilpin D, Kaplan FT, Houston A, Kaufman GJ, Cohen BM et al. Efficacy and safety of concurrent colla¬genase clostridium histolyticum injections for multiple Dupuytren contractures. J Hand Surg Am. 2014;39:57-64. doi:10.1016/j.jhsa.2013.10.002.
21. Obed D, Salim M, Schlottmann F, Bingoel AS, Panayi AC, Dastagir K et al. Short-term efficacy and adverse effects of collagenase clostridium histolyticum injections, percutaneous needle fasciotomy and limited fasciotomy in the treatment of Dupuytren’s contracture: a network meta-analysis of randomized controlled trials. BMC Musculoskelet Disord. 2022;23:939. doi:10.1186/s12891-022-05894-6.
22. Dias J, Arundel C, Tharmanathan P, Keding A, Welch C, Corbacho B et al. Dupuytren’s interventions surgery versus collagenase (DISC) trial: study protocol for a pragmatic, two-arm parallel-group, non-inferiority randomised controlled trial. Trials. 2021;22(1):671. doi:10.1186/s13063-021-05595-w.
23. Żyluk A. Dupuytren’s disease – what’s new: a review. Pol Przegl Chir. 2023; 95(6): 53-61. https://doi.org/10.5604/01.3001.0016.0058.
24. Almadani Y, Vorstenbosch J, Efanov JI, Xu L. Dupuytren’s Disease: an Outcomes-Focused Update. Sermin Plast Surg. 2021;35:216-22. doi:10.1055/s-0041-1731631.
25. Stepić N, Končar J, Rajović M. The influence of Dupuytren's disease fingers contracture degree on surgical treatment outcome. Vojnosanit Pregl. 2017; 74(1): 19–23. doi: 10.2298/VSP150331103S.
26. Dias JJ, Aziz S. Fasciectomy for Dupuytren Contracture. Hand Clinics. 2018;34:351-66. doi:10.1016/j.hcl.2018.04.002.
27. Kan HJ, Verrijp FW, Hovious SER, van Nieuwenhoven CA, Group DD, Selles RW. Correction: Recurrence of Dupuytren's contracture: A consensus-based definition. PLoS One. 2019;14(4):e0216313. doi:10.1371/journal.pone.0216313.
28. Van Nuffel M, Meulyzer C, Vrancken C, Van den Kerckhove E, De Smet L, Degreef I. Treatment practice for Dupuytren disease in Belgium before 2020: results from an online survey. Acta Orthop Belg. 2022;88(2):399-409. doi:10.52628/88.2.9764.
29. Taheri P, Salek N, Mousavi M, Maghroori R. The effect of Shock Wave Therapy on Improving the Symptoms and Function of Patients with Dupuytren’s Contracture. Adv Biomed Res. 2022; 11:3. doi:10.4103/abr.abr_155_21.
30. Aglen T. Matre KH, Lind C, Selles RW, Assmus J, Taule T. Hand therapy or not following collagenase treatment for Dupuytren’s contracture? Protocol for a randomised controlled trial. BMC Musculoskelet Disord. 2019;20:387. doi:10.1186/s12891-019-2712-z.
2. Elliot D. The early history of Dupuytren’s disease. Hand Clin. 1999;15(1):1-v.
3. Salari N, Heydari M, Hassanabadi M, Kazeminia M, Farshchian N, Niaparast M, et al. The worldwide prevalence of the Dupuytren disease: a comprehensive systematic review and meta-analysis. J Orthop Surg Res. 2020;15(1):495. doi: 10.1186/s13018-020-01999-7.
4. Ng M, Lawson DJ, Winney B, Furniss D. Is Dupuytren’s disease really a ‘disease of the Vikings’?. J Hand Surg Eur Vol. 2020;45:273-79. doi:10.1177/1753193419882851.
5. Ng M, Thakkar D, Southam L, Werker P, Ophoff R, Becker K et al. A genome-wide Association Study of Dupuytren Disease Reveals 17 Additional Variants Implicated in Fibrosis. Am J Hum Genet. 2017;101:417-27. doi:10.1016/j.ajhg.2017.08.006.
6. Todorović Z, Jovanović B, Stoiljković G. Dipitrenova kontraktura – naša iskustva. Apollinem medicum et aesculapium. 2012; 10(3):12-15.
7. Nikolić J, Janjić Z, Momčilovć D, Ninković S, Harhai V. Plantarna fibromatoza i Dupuytren-ova kontraktura kod adolescenta. Vojnosanit Pregl. 2011; 68(10):886-90. doi: 10.2298/VSP1110886N.
8. Fernando JJ, Fowler C, Graham T, Terry K, Grocott P, Sandford F. Pre-operative hand therapy management of Dupuytren's disease: A systematic review. Hand Ther. 2024;29(2):52-61. doi: 10.1177/17589983241227162.
9. Dutta A, Jayasinghe G, Deore S, Wahed K, Bhan K, Bakti N, et al. Dupuytren’s contracture—current concepts. J Clin Orthop Trauma. 2020;11(4):590-96. doi: 10.1016/j.jcot.2020.03.026.
10. Walthall J, Anand P, Rehman UH. Dupuytren Contracture. [Updated 2023 Feb 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526074/
11. Larocerie-Salgado J, Davidson J, Fenton P. Nonoperative Treatment of Dupuytren's Contracture: The Use of Ultrasound Imaging to Assess Efficacy. J Hand Microsurg. 2024;16(1):100003. doi:10.1055/s-0042-1748780
12. Lambi AG, Popoff SN, Benhaim P, Barbe MF. Pharmacotherapies in Dupuytren Disease: Current and Novel Strategies. J Hand Surg Am. 2023;48(8):810-21. doi:10.1016/j.jhsa.2023.02.003
13. Park JW, Kim ST, Lee KS, Gong HS. Vitamin D status in Dupuytren’s disease: Association with clinical status and vitamin D receptor expression. J Plast Reconstr Aesthet Surg. 2022; 75:1916-22. doi:10.1016/j.bjps.2022.01.012.
14. Yildiz S, Karacaoğlu E, Pehlivan O. Hyperbaric oxygen for the treatment of early-phase Dupuytren's contracture. Microsurgery. 2004;24(1):26-29. doi:10.1002/micr.10198.
15. Davis SM, Chang EY. Dupuytren's contracture treated with botulinum toxin A injection. Arch Clin Cases. 2021;7(4):63-67. doi: 10.22551/2020.29.0704.10175.
16. National Institute for Health and Care Excellence [Internet]. Nice: Radiation therapy for early Dupuytren’s disease. c2023 [cited 2021 Mar 8]. Available from: https://www.nice.org.uk/guidance/ipg573/resources/radiation-therapy-for-early-dupuytrens-disease-pdf-1899872106511813.
17. Reuttermann M, Hermann MR, Khatib Chatidi K, Werker PMN. Dupuytren’s Disease - Etiology and Treatment. Dtsch Arztebl Int. 2021;19:781-88. doi:10.3238/arztebl.m2021.0325.
18. Kuboi T, Tajika T, Endo F, Goto W, Nakajima I, Hasegawa S, et al. Collagenase Clostridium histolyticum Injection Therapy Improves Health-related Quality of Life in Patients with Dupuytren's Disease. Prog Rehabil Med. 2021;6:20210023. doi: 10.2490/prm.20210023.
19. Warwick D, Arner M, Pajardi G, Szabo Z, Masmejean EH, Fores J et al. Collagenase clostridium histolyticum in patients with Duppuytren’s contracture: results from POINT X, an open label study of clinical and patient reported outcomes. J Hand Surg Eur. 2015;40:124-32. doi:10.1177/1753193413519926.
20. Coleman S, Gilpin D, Kaplan FT, Houston A, Kaufman GJ, Cohen BM et al. Efficacy and safety of concurrent colla¬genase clostridium histolyticum injections for multiple Dupuytren contractures. J Hand Surg Am. 2014;39:57-64. doi:10.1016/j.jhsa.2013.10.002.
21. Obed D, Salim M, Schlottmann F, Bingoel AS, Panayi AC, Dastagir K et al. Short-term efficacy and adverse effects of collagenase clostridium histolyticum injections, percutaneous needle fasciotomy and limited fasciotomy in the treatment of Dupuytren’s contracture: a network meta-analysis of randomized controlled trials. BMC Musculoskelet Disord. 2022;23:939. doi:10.1186/s12891-022-05894-6.
22. Dias J, Arundel C, Tharmanathan P, Keding A, Welch C, Corbacho B et al. Dupuytren’s interventions surgery versus collagenase (DISC) trial: study protocol for a pragmatic, two-arm parallel-group, non-inferiority randomised controlled trial. Trials. 2021;22(1):671. doi:10.1186/s13063-021-05595-w.
23. Żyluk A. Dupuytren’s disease – what’s new: a review. Pol Przegl Chir. 2023; 95(6): 53-61. https://doi.org/10.5604/01.3001.0016.0058.
24. Almadani Y, Vorstenbosch J, Efanov JI, Xu L. Dupuytren’s Disease: an Outcomes-Focused Update. Sermin Plast Surg. 2021;35:216-22. doi:10.1055/s-0041-1731631.
25. Stepić N, Končar J, Rajović M. The influence of Dupuytren's disease fingers contracture degree on surgical treatment outcome. Vojnosanit Pregl. 2017; 74(1): 19–23. doi: 10.2298/VSP150331103S.
26. Dias JJ, Aziz S. Fasciectomy for Dupuytren Contracture. Hand Clinics. 2018;34:351-66. doi:10.1016/j.hcl.2018.04.002.
27. Kan HJ, Verrijp FW, Hovious SER, van Nieuwenhoven CA, Group DD, Selles RW. Correction: Recurrence of Dupuytren's contracture: A consensus-based definition. PLoS One. 2019;14(4):e0216313. doi:10.1371/journal.pone.0216313.
28. Van Nuffel M, Meulyzer C, Vrancken C, Van den Kerckhove E, De Smet L, Degreef I. Treatment practice for Dupuytren disease in Belgium before 2020: results from an online survey. Acta Orthop Belg. 2022;88(2):399-409. doi:10.52628/88.2.9764.
29. Taheri P, Salek N, Mousavi M, Maghroori R. The effect of Shock Wave Therapy on Improving the Symptoms and Function of Patients with Dupuytren’s Contracture. Adv Biomed Res. 2022; 11:3. doi:10.4103/abr.abr_155_21.
30. Aglen T. Matre KH, Lind C, Selles RW, Assmus J, Taule T. Hand therapy or not following collagenase treatment for Dupuytren’s contracture? Protocol for a randomised controlled trial. BMC Musculoskelet Disord. 2019;20:387. doi:10.1186/s12891-019-2712-z.
Objavljeno
2025/01/23
Rubrika
Članci
Autori koji objavljuju u ovom časopisu pristaju na sledeće uslove:
- Autori zadržavaju autorska prava i pružaju časopisu pravo prvog objavljivanja rada i licenciraju ga "Creative Commons Attribution licencom" koja omogućava drugima da dele rad, uz uslov navođenja autorstva i izvornog objavljivanja u ovom časopisu.
- Autori mogu izraditi zasebne, ugovorne aranžmane za neekskluzivnu distribuciju članka objavljenog u časopisu (npr. postavljanje u institucionalni repozitorijum ili objavljivanje u knjizi), uz navođenje da je članak izvorno objavljen u ovom časopisu.
- Autorima je dozvoljeno i podstiču se da postave objavljeni članak onlajn (npr. u institucionalni repozitorijum ili na svoju internet stranicu) pre ili tokom postupka prijave rukopisa, s obzirom da takav postupak može voditi produktivnoj razmeni ideja i ranijoj i većoj citiranosti objavljenog članka (Vidi Efekti otvorenog pristupa).